<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer Res</journal-id><journal-title-group><journal-title>Breast Cancer Research : BCR</journal-title></journal-title-group><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28851423</article-id><article-id pub-id-type="pmc">5574249</article-id><article-id pub-id-type="publisher-id">861</article-id><article-id pub-id-type="doi">10.1186/s13058-017-0861-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The <italic>BRCA1</italic>ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Severson</surname><given-names>Tesa M.</given-names></name><address><email>t.severson@nki.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wolf</surname><given-names>Denise M.</given-names></name><address><email>Denise.Wolf@ucsf.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yau</surname><given-names>Christina</given-names></name><address><email>cyau@buckinstitute.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Peeters</surname><given-names>Justine</given-names></name><address><email>justinepeeters@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wehkam</surname><given-names>Diederik</given-names></name><address><email>diederik.wehkamp@agendia.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schouten</surname><given-names>Philip C.</given-names></name><address><email>p.schouten@nki.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chin</surname><given-names>Suet-Feung</given-names></name><address><email>Suet-Feung.Chin@cruk.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Majewski</surname><given-names>Ian J.</given-names></name><address><email>majewski@wehi.EDU.AU</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Michaut</surname><given-names>Magali</given-names></name><address><email>m.michaut@nki.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Bosma</surname><given-names>Astrid</given-names></name><address><email>a.bosma@nki.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Pereira</surname><given-names>Bernard</given-names></name><address><email>bernard.pereira@cruk.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bismeijer</surname><given-names>Tycho</given-names></name><address><email>t.bismeijer@nki.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wessels</surname><given-names>Lodewyk</given-names></name><address><email>l.wessels@nki.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Caldas</surname><given-names>Carlos</given-names></name><address><email>Carlos.Caldas@cruk.cam.ac.uk</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bernards</surname><given-names>Ren&#x000e9;</given-names></name><address><email>r.bernards@nki.nl</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Simon</surname><given-names>Iris M.</given-names></name><address><email>irissimon@yahoo.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Glas</surname><given-names>Annuska M.</given-names></name><address><email>Annuska.Glas@agendia.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Linn</surname><given-names>Sabine</given-names></name><address><email>s.linn@nki.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>van &#x02018;t Veer</surname><given-names>Laura</given-names></name><address><email>Laura.Vantveer@ucsf.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution>Division of Molecular Pathology, </institution><institution>Netherlands Cancer Institute, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2297 6811</institution-id><institution-id institution-id-type="GRID">grid.266102.1</institution-id><institution/><institution>University of California, </institution></institution-wrap>San Francisco, CA USA </aff><aff id="Aff3"><label>3</label>Agendia NV, Amsterdam, The Netherlands </aff><aff id="Aff4"><label>4</label>CRUK Cambridge Institute, Cambridge, UK </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution>Division of Molecular Carcinogenesis, </institution><institution>Netherlands Cancer Institute, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.1042.7</institution-id><institution>Current address: Division of Cancer and Haematology, </institution><institution>Walter and Eliza Hall Institute of Medical Research, </institution></institution-wrap>Melbourne, Australia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2097 4740</institution-id><institution-id institution-id-type="GRID">grid.5292.c</institution-id><institution/><institution>Faculty of EEMCS, Delft University of Technology, </institution></institution-wrap>Delft, The Netherlands </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution>Division Medical Oncology, </institution><institution>Netherlands Cancer Institute, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Department of Pathology, </institution><institution>University Medical Center Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>19</volume><elocation-id>99</elocation-id><history><date date-type="received"><day>27</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Patients with <italic>BRCA1</italic>-like tumors correlate with improved response to DNA double-strand break-inducing therapy. A gene expression-based classifier was developed to distinguish between <italic>BRCA1</italic>-like and non-<italic>BRCA1</italic>-like tumors. We hypothesized that these tumors may also be more sensitive to PARP inhibitors than standard treatments.</p></sec><sec><title>Methods</title><p id="Par2">A diagnostic gene expression signature (<italic>BRCA1</italic>ness) was developed using a centroid model with 128 triple-negative breast cancer samples from the EU FP7 RATHER project. This <italic>BRCA1</italic>ness signature was then tested in HER2-negative patients (<italic>n</italic>&#x02009;=&#x02009;116) from the I-SPY 2 TRIAL who received an oral PARP inhibitor veliparib in combination with carboplatin (V-C), or standard chemotherapy alone. We assessed the association between <italic>BRCA1</italic>ness and pathologic complete response in the V-C and control arms alone using Fisher&#x02019;s exact test, and the relative performance between arms (biomarker&#x02009;&#x000d7;&#x02009;treatment interaction, likelihood ratio <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) using a logistic model and adjusting for hormone receptor status (HR).</p></sec><sec><title>Results</title><p id="Par3">We developed a gene expression signature to identify <italic>BRCA1</italic>-like status. In the I-SPY 2 neoadjuvant setting the <italic>BRCA1</italic>ness signature associated significantly with response to V-C (<italic>p</italic>&#x02009;=&#x02009;0.03), but not in the control arm (<italic>p</italic>&#x02009;=&#x02009;0.45). We identified a significant interaction between <italic>BRCA1</italic>ness and V-C (<italic>p</italic>&#x02009;=&#x02009;0.023) after correcting for HR.</p></sec><sec><title>Conclusions</title><p id="Par4">A genomic-based <italic>BRCA1</italic>-like signature was successfully translated to an expression-based signature (<italic>BRC1A</italic>ness). In the I-SPY 2 neoadjuvant setting, we determined that the <italic>BRCA1</italic>ness signature is capable of predicting benefit of V-C added to standard chemotherapy compared to standard chemotherapy alone.</p></sec><sec><title>Trial registration</title><p id="Par5">I-SPY 2 TRIAL beginning December 31, 2009: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2), <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01042379">NCT01042379</ext-link>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13058-017-0861-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Neoadjuvant</kwd><kwd><italic>BRCA</italic>ness</kwd><kwd>PARP inhibition</kwd><kwd>Triple-negative breast cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution>European FP7 RATHER Project</institution></funding-source><award-id>258967</award-id><principal-award-recipient><name><surname>Bernards</surname><given-names>Ren&#x000e9;</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>I-SPY 2 Trial investigators</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par29">Histological subtype information in breast cancer is clinically relevant for treatment purposes but insufficient to describe all tumor heterogeneity [<xref ref-type="bibr" rid="CR1">1</xref>]. The basal-like molecular subtype, which typically expresses cytokeratins 5/6 and EGFR, frequently overlaps with the histological subtype of triple-negative (TN) breast cancer [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. TN breast cancer is described by the absence of ER&#x003b1;/PR and HER2 expression and poor overall prognosis [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Because of the lack of available targeted therapies for this subtype, the clinical impact of target discovery for patients with TN breast cancer is potentially significant.</p><p id="Par30">Hereditary germline <italic>BRCA1</italic> mutations are found in around 12% of all TN breast cancers [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. BRCA1 plays a critical role in error-free DNA double-strand break repair via homologous recombination, and deficiency can result in genomic instability [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Differential gene expression patterns in <italic>BRCA1</italic> mutant tumors versus nonmutant tumors have been identified previously [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Because of the relative rarity of <italic>BRCA1</italic> mutation in the general breast cancer population [<xref ref-type="bibr" rid="CR15">15</xref>], however, these studies are often underpowered, making clinical impact for mutation carriers limited. Furthermore, the capacity of these signatures to predict response to targeted treatments such as PARP inhibitors has not been thoroughly explored in the randomized clinical trial setting.</p><p id="Par31">BRCA1-mutated/promoter-methylated TN tumors with a specific pattern of copy number alterations are termed <italic>BRCA1</italic>-like [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. &#x02018;<italic>BRCA</italic>ness&#x02019; describes tumors with molecular features of BRCA1-mutated tumors [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Interestingly, the whole group of <italic>BRCA1</italic>-like tumors responds well to DNA double-strand break-inducing agents and intensifying chemotherapy regardless of their <italic>BRCA1</italic> mutation/promoter methylation status [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. These findings suggest that a relatively large portion of TN breast cancers may be susceptible to targeted therapies such as PARP inhibitors. The efforts of many groups have resulted in various classifiers for <italic>BRCA</italic>ness, typically based on mutation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] or homologous recombination repair deficiency (HRD) markers [<xref ref-type="bibr" rid="CR26">26</xref>] and using gene expression data as an input. Recent work has found that an assay designed to detect <italic>BRCA</italic>ness using HRD as a biomarker failed to predict for carboplatin response [<xref ref-type="bibr" rid="CR27">27</xref>], illustrating the challenges of generating a signature with the capacity to predict treatment effect [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par32">Molecular subgroups within the TN subtype have differential benefit from therapies [<xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. In addition, previous work in TN tumors has determined that differentially expressed genes between <italic>BRCA1</italic>-like and non-<italic>BRCA1</italic>-like tumors center around DNA repair [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and may lead to new information for clinical therapeutic decisions. A test based on gene expression levels may also lead to insight into the mechanisms which result in tumors with <italic>BRCA1</italic>-like features. We developed a 77-gene signature to identify samples with a <italic>BRCA1</italic>-like gene expression pattern we term <italic>BRCA1</italic>ness with a sensitivity and specificity of 96.7% and 73.1%, respectively. We explored this signature&#x02019;s ability to predict response to the PARP inhibitor veliparib in combination with carboplatin (V-C) in the I-SPY 2 TRIAL, a phase 2, multicenter, adaptively randomized trial designed to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer, where V-C graduated in the TN signature [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]. Investigation of the <italic>BRCA1</italic>ness signature was part of a further evaluation of additional biomarkers in this setting. In this study, we aimed to answer the clinical question in the I-SPY 2 external validation set of whether to treat with PARP inhibition based on the well-studied mechanism of HRD (identified by our biomarker <italic>BRCA1</italic>ness).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Discovery set patient characterization and microarray data generation</title><p id="Par33">The collaborative European Union-funded effort FP7 RATHER project (<italic>Ra</italic>tional <italic>Ther</italic>apy for Breast Cancer) aims to integrate gene expression profiling, copy number variation, kinome variation and kinase activation status in an effort to identify new targets for therapy of difficult-to-treat breast cancer subtypes, including TN breast cancer (<ext-link ext-link-type="uri" xlink:href="http://www.ratherproject.com/">www.ratherproject.com</ext-link>). The RATHER project retrospectively identified 128 TN breast cancer patients with long-term follow-up in total: 70 from Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands and 58 from Addenbrooke&#x02019;s Hospital, Cambridge, UK.</p><p id="Par34">The primary inclusion criterion for the RATHER cohort was availability of sufficient isolated frozen RNA tissue in the tissue bank and diagnostic information indicative of TN breast cancer. We enriched for frozen tumors with 30% or greater tumor content (2 x 8-&#x003bc;m serial sections, hematoxylin and eosin stained). The local medical ethics authorities of both centers approved the collection protocols. Sectioning of tumor tissue and RNA isolation were performed as described previously [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par35">Samples with RIN value&#x02009;&#x0003e;&#x02009;5 according to 2100 Bioanalyzer (Agilent Technologies) assessment were selected for further analysis. Gene expression data were generated as described previously [<xref ref-type="bibr" rid="CR37">37</xref>]. Briefly, feature signal intensities were processed and extracted using the &#x02018;limma&#x02019; R package with background subtraction using an offset of 10 and log<sub>2</sub> transformed data. Probe intensities were quantile normalized with in-house R scripts and missing values (including probes with signal intensities&#x02009;&#x0003c;&#x02009;1 after preprocessing) were imputed by the 10 nearest-neighbor method. A biobank batch effect was adjusted using ComBat [<xref ref-type="bibr" rid="CR38">38</xref>]. Genes with multiple probes were summarized by the first principal component of a correlating subset.</p></sec><sec id="Sec4"><title><italic>BRCA1</italic>-like classification</title><p id="Par36">The multiplex ligation-dependent probe amplification (MLPA) method was used to generate copy number profiles for the determination of the <italic>BRCA1</italic>-like status of the tumors. The assay was performed, fragments analyzed and data normalized according to the manufacturer&#x02019;s protocol (MRC-Holland). Class prediction (<italic>BRCA1</italic>-like/non-<italic>BRCA1</italic>-like) was carried out on the normalized data according to published instructions [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec5"><title>Gene signature development</title><p id="Par37">Signature development was performed using Partek Genomics Suite (partek.com) (categorical signature) and Matlab (<ext-link ext-link-type="uri" xlink:href="https://mathworks.com/">https://mathworks.com/</ext-link>) (translation to continuous score) on 128 samples. Top variable genes (variance &#x0003e;1 across all samples) were used for the model input (<italic>N</italic>&#x02009;=&#x02009;2049). The classification model of diagonal linear discriminant analysis (DLDA) with equal prior probabilities was run to select the signature genes. Groups of genes ranked by their significance in a univariate ANOVA examining the <italic>BRCA1</italic>-like/non-<italic>BRCA1</italic>-like MLPA status were tested (groups from 1 to 100, in increments of 1). Single-level leave-one-out cross validation (LOOCV) with the maximum number of partitions was used to internally validate and calculate the performance of the model.</p><p id="Par38">The significant number of genes in the model (<italic>n</italic>&#x02009;=&#x02009;77, Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) was selected based on the ROC area under the curve (AUC as specified by Partek). After the model is run, each sample is allocated a posterior probability for each class (<italic>BRCA1</italic>-like and non-<italic>BRCA1</italic>-like) and the sample is assigned to the class with the highest posterior probability (<italic>BRCA1</italic>ness). This categorical signature was then transferred to the diagnostic setting to better comply with quality and regulatory requirements using a nearest centroid model; a robust method with both reasonable and favorable characteristics for many measurements on a modest amount of patients [<xref ref-type="bibr" rid="CR39">39</xref>]. Briefly, raw full genome data were normalized and class centroids were calculated (median per gene) for each of the 77 genes for each class (<italic>BRCA1</italic>ness/non-<italic>BRCA1</italic>ness) using the discovery set. These calculated centroids were used as the template for <italic>BRCA1</italic>ness/non-<italic>BRCA1</italic>ness. Pearson correlations of each new sample with the <italic>BRCA1</italic>ness/non-<italic>BRCA1</italic>ness templates were calculated (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1) and combined into a single continuous score by subtracting the correlation to the non-<italic>BRC1A</italic>ness template from the correlation to the <italic>BRC1A</italic>ness template. In order for a sample to be classified as <italic>BRCA1</italic>ness, a threshold was established with a high sensitivity while preserving specificity close to 0.75. The classification threshold was set at &#x02013;0.3; that is, a sample with a <italic>BRCA1</italic>ness score&#x02009;&#x0003e;&#x02009;&#x02013;0.3 was classified as <italic>BRCA1</italic>ness and a sample with a score&#x02009;&#x0003c;&#x02009;&#x02013;0.3 was classified as non-<italic>BRCA1</italic>ness.</p></sec><sec id="Sec6"><title>I-SPY 2 TRIAL</title><p id="Par39">The I-SPY 2 TRIAL is a standing multicenter, phase 2 platform trial to screen experimental regimens in combination with standard chemotherapy in the neoadjuvant treatment of breast cancer. Patients are adaptively randomized into one of four experimental arms or a control arm (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR35">35</xref>]. In this portion of the I-SPY 2 TRIAL, eligible patients received weekly paclitaxel at 80&#x000a0;mg/m<sup>2</sup> (T) i.v. for 12 doses alone (control), or in combination with an experimental regimen. Patients randomized to V-C received 50&#x000a0;mg of veliparib by mouth twice daily for 12&#x000a0;weeks and carboplatin at AUC 6 on weeks 1, 4, 7 and 10 concurrent with weekly paclitaxel. Following paclitaxel&#x02009;&#x000b1;&#x02009;V-C, all patients received doxorubicin 60&#x000a0;mg/m<sup>2</sup> and cyclophosphamide 600&#x000a0;mg/m<sup>2</sup> (AC) i.v. every 2&#x02013;3 weeks for four doses with myeloid growth factor support as appropriate per protocol followed by surgery that included axillary node sampling. The V-C arm was open to HER2-negative patients; and was graduated in the TN group. The <italic>BRCA1</italic>ness signature was one of the qualifying dichotomous biomarkers assessed as a predictor of response to V-C relative to standard chemotherapy.<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT diagram. CONSORT diagram indicating how patients were randomized for the I-SPY 2 TRIAL</p></caption><graphic xlink:href="13058_2017_861_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par40">To assess the <italic>BRCA1</italic>ness signature in this validation set as a specific biomarker of V-C response, gene expression data from 116 HER2-negative patients (V-C, <italic>n</italic>&#x02009;=&#x02009;72 and concurrent controls, <italic>n</italic>&#x02009;=&#x02009;44) were analyzed. A Customized Agilent 44&#x000a0;K array (Agendia) was used to evaluate the 77-gene signature <italic>BRCA1</italic>ness classification. The association between <italic>BRCA1</italic>ness classification and response in the V-C and control arms alone was assessed using Fisher&#x02019;s exact test, and the relative performance between arms (biomarker&#x02009;&#x000d7;&#x02009;treatment interaction, likelihood ratio test) using a logistic model. We included adjustment for hormone receptor status (HR/TN) and tumor size in our model. Our sample size is small, and thus statistical calculations (<italic>p</italic> values) are descriptive rather than inferential. This analysis does not adjust for multiplicities of other biomarkers evaluated in the trial but outside this study.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Signature development</title><p id="Par41">We developed a <italic>BRCA1</italic>ness signature using whole genome gene expression data. The signature has been developed on fresh frozen (FF) breast tumors that were categorized as either <italic>BRCA1</italic>-like or non-<italic>BRCA1</italic>-like using a DNA copy number MLPA-based classifier [<xref ref-type="bibr" rid="CR16">16</xref>], and endeavors to predict <italic>BRCA1</italic>-like tumors with a high sensitivity/specificity rate.</p><p id="Par42">Forty-eight percent of the tumors (61/128) in the discovery cohort were classified as <italic>BRCA1</italic>-like and the remainder was assigned to the non-<italic>BRCA1</italic>-like class. We employed the gene expression profiles of the tumors, DLDA and the labels assigned by the MLPA-based classifier to train a classifier that distinguishes between the two classes. Using the ROC area under the curve model (AUC) as the performance criterion we identified a 77-gene signature that resulted in the highest performance (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Sensitivity and specificity for detecting <italic>BRCA1</italic>-like status samples using <italic>BRCA1</italic>ness</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>MLPA <italic>BRCA1</italic>-like</th><th>MLPA non-<italic>BRCA1</italic>-like</th></tr></thead><tbody><tr><td>
<italic>BRCA1</italic>ness positive</td><td>59</td><td>18</td></tr><tr><td>
<italic>BRCA1</italic>ness negative</td><td>2</td><td>49</td></tr><tr><td rowspan="2"/><td>Sensitivity</td><td>Specificity</td></tr><tr><td>96.7%</td><td>73.1%</td></tr></tbody></table><table-wrap-foot><p>
<italic>MLPA</italic> multiplex ligation-dependent probe amplification</p></table-wrap-foot></table-wrap>
</p><p id="Par43">Unsupervised hierarchical clustering of the genes in the 77-gene signature indicates separation between the classes (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). We transferred the signature to a diagnostic setting using a nearest centroid-based algorithm. The sensitivity and specificity for detecting <italic>BRCA1</italic>-like status as defined by MLPA were 96.7% and 73.1%, respectively. Using Ingenuity Pathway Analysis (Qiagen) to identify key biological processes associated with the 77 genes in the <italic>BRCA1</italic>ness 77-gene signature, we found cellular assembly and control and DNA replication, recombination and repair to be among the top associated pathways and functions (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). In addition, we observed serine and glycine biosynthesis to be associated with the 77-gene signature genes, indicating that these genes may be responsible for reprogramming of metabolic processes, which can lead to tumor progression (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). Supporting the pathway and molecular function results, network analysis revealed a network centered upon cell the cycle control regulator cyclin A (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Unsupervised hierarchical clustering of 77 genes in the 128 discovery set samples. The 77 genes were derived from a supervised analysis to identify those genes most informative in distinguishing <italic>BRCA1</italic>-like from non-<italic>BRCA1</italic>-like TN breast cancers [<xref ref-type="bibr" rid="CR33">33</xref>]. Scaled expression value denoted as <italic>Z</italic> score (<italic>red&#x02013;blue</italic> scale: <italic>red</italic> indicates high expression and <italic>blue</italic> indicates low expression). Information bar indicates MLPA <italic>BRCA1</italic>-like status: true (<italic>green</italic>) or false (<italic>brown</italic>). <italic>MLPA</italic> multiplex ligation-dependent probe amplification (Color figure online)</p></caption><graphic xlink:href="13058_2017_861_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig. 3</label><caption><p>The 77-gene signature network analysis. <bold>a</bold> Significant canonical pathways (<italic>top</italic>) and molecular functions (<italic>bottom</italic>). Negative log <italic>p</italic> value is on the <italic>x</italic> axis. <bold>b</bold> Network analysis of the 77 genes in the <italic>BRCA1</italic>ness signature. <italic>Grey shading</italic> indicates genes found in signature, <italic>solid lines</italic> show direct relationships between proteins and <italic>dashed lines</italic> show indirect relationships</p></caption><graphic xlink:href="13058_2017_861_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec9"><title>I-SPY 2 TRIAL</title><p id="Par44">The <italic>BRCA1</italic>ness signature was applied to 116 HER2-negative patients (V-C, <italic>n</italic>&#x02009;=&#x02009;72 and concurrent controls, <italic>n</italic>&#x02009;=&#x02009;44). Fifty-five patients were classified as <italic>BRCA1</italic>ness. Fourteen percent of these patients were hormone receptor-positive (ER&#x003b1;/PR) and HER2-negative. The distribution of pathological complete response (pCR) rates among <italic>BRCA1</italic>ness and non-<italic>BRCA1</italic>ness groups is shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref> [<xref ref-type="bibr" rid="CR36">36</xref>] and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Association between the <italic>BRCA1</italic>ness classification and patient response was seen in the V-C arm (OR&#x02009;=&#x02009;3.2, <italic>p</italic>&#x02009;=&#x02009;0.03) but not in the control arm (OR&#x02009;=&#x02009;0.39, <italic>p</italic>&#x02009;=&#x02009;0.45) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>). A significant biomarker&#x02009;&#x000d7;&#x02009;treatment interaction (<italic>p</italic>&#x02009;=&#x02009;0.025) was also observed. Although there is enrichment for TN samples in the <italic>BRCA1</italic>ness group in univariate analysis (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), this interaction remains significant upon adjusting for HR (<italic>p</italic>&#x02009;=&#x02009;0.023) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4c</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>I-SPY 2 TRIAL. <bold>a</bold> Mosaic plot depicting the number of patients with pathological complete response (<italic>pCR</italic>) in each treatment group and signature group. <italic>Top row</italic> indicates patients in the trial enrolled in the control arm and <italic>bottom row</italic> indicates patients in the V-C arm. Number of patients with pCR is shown in <italic>green</italic> and number of patients without pCR is shown in <italic>tan. Black outlined boxes</italic> indicate the patients with a non-<italic>BRCA1</italic>ness status (<italic>left</italic>), <italic>red outlined boxes</italic> depict those with <italic>BRCA1</italic>ness status (<italic>right</italic>). <bold>b</bold> Histological subtype of the patients in the trial divided by treatment arm (V-C) and control arm and pCR rate per group. <bold>c</bold> Odds ratio (<italic>OR</italic>) and likelihood ratio test (<italic>LR</italic>) for treatment and control arms of the trial and the biomarker x treatment interaction test. <italic>HER2</italic> human epidermal growth factor receptor 2, <italic>HR</italic> hormone receptor status, <italic>TN</italic> triple-negative, <italic>V/C</italic> veliparib-carboplatin (Color figure online)</p></caption><graphic xlink:href="13058_2017_861_Fig4_HTML" id="MO4"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th>Non-<italic>BRCA1</italic>ness</th><th>
<italic>BRCA1n</italic>ess</th><th rowspan="2">
<italic>p</italic> value</th></tr><tr><th>(<italic>N</italic>&#x02009;=&#x02009;61)</th><th>(<italic>N</italic>&#x02009;=&#x02009;55)</th></tr></thead><tbody><tr><td colspan="4">Treatment</td></tr><tr><td>&#x02003;Control</td><td>27 (44.3)</td><td>17 (30.9)</td><td rowspan="2">0.198<sup>a</sup>
</td></tr><tr><td>&#x02003;Veliparib/carboplatin</td><td>34 (55.7)</td><td>38 (69.1</td></tr><tr><td colspan="4">Hormone receptor status</td></tr><tr><td>&#x02003;HR+</td><td>48 (78.7)</td><td>8 (14.5)</td><td rowspan="2">&#x0003c;0.05<sup>a</sup>
</td></tr><tr><td>&#x02003;TN</td><td>13 (21.3)</td><td>47 (85.5)</td></tr><tr><td colspan="4">Tumor size (cm)</td></tr><tr><td>&#x02003;0&#x02013;1</td><td>0 (0)</td><td>0 (0)</td><td rowspan="4">0.496<sup>a</sup>
</td></tr><tr><td>&#x02003;&#x0003e;1&#x02013;2</td><td>0 (0)</td><td>1 (1.8)</td></tr><tr><td>&#x02003;&#x0003e;2&#x02013;5</td><td>40 (65.6)</td><td>31 (56.4)</td></tr><tr><td>&#x02003;&#x0003e;5</td><td>19 (31.4)</td><td>22 (40.0)</td></tr></tbody></table><table-wrap-foot><p>Data presented as number (%)</p><p>
<italic>HR</italic> hormone receptor status, <italic>TN</italic> triple-negative</p><p>
<sup>a</sup>Pearson&#x02019;s chi-squared test</p></table-wrap-foot></table-wrap>
</p><p id="Par45">In addition we found that the interaction also remains significant when adjusting for tumor size and HR (<italic>p</italic>&#x02009;=&#x02009;0.038). We use the likelihood ratio test to formally demonstrate that the logistic regression with the addition of the HR (and tumor size) terms does not provide a better fit to the data. When the hormone receptor-positive <italic>BRCA1</italic>ness classified patients are added to the graduating TN subset, the OR associated with V-C is 4.03. This is comparable to that of the TN alone (OR&#x02009;=&#x02009;4.04), while increasing the prevalence of &#x02018;biomarker-positive&#x02019; predicted V-C sensitive patients by 8%.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par46">At around 15% of all breast cancers, the TN breast cancer subtype impacts a significant proportion of women [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. TN breast cancer tends to be aggressive independent of other known prognostic factors [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Current guidelines indicate that standard therapy for TN breast cancer is chemotherapy [<xref ref-type="bibr" rid="CR2">2</xref>]. Unfortunately, these tumors typically metastasize early despite therapy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. This poor response to treatment may be due to the fact that the TN subtype itself is made of molecular subgroups. Conversely, molecular data from these subgroups may indicate a targeted therapy, which is likely to benefit patients.</p><p id="Par47">Because of results in preclinical models, <italic>BRCA1</italic> mutation carriers of multiple tumor types have been enrolled in clinical trials with PARP inhibitors [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. Currently, there are no other predictive biomarkers for PARP inhibitors other than the germline BRCA1 mutation status, and the issue with that biomarker is that it only captures a small subgroup of all patients that may benefit from carboplatin/veliparib [<xref ref-type="bibr" rid="CR8">8</xref>]. Previous work has shown that genomic instability patterns are related to <italic>BRCA1</italic> mutation/methylation and that these patterns can be used to classify tumors are <italic>BRCA1</italic>-like or non-BRCA1-like [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. These <italic>BRCA1</italic>-like tumors make up a larger group than <italic>BRCA1</italic> mutant or methylated alone, and importantly they respond well to DNA double-strand break-inducing chemotherapies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. We have developed a gene expression signature that is capable of identifying <italic>BRCA1</italic>-like samples with a high sensitivity/specificity rate (<italic>BRCA1</italic>ness).</p><p id="Par48">Pathway analysis reveals that the genes in this signature are associated closely with cell cycle and cancer networks. We also observed a significant association with serine and glycine biosynthesis pathways with the genes of the signature. This is of particular interest because it has been recently shown that aerobic glycolysis signaling can promote tumor growth in breast cancer cell lines that are TN [<xref ref-type="bibr" rid="CR45">45</xref>], indicating that the poor outcome for patients with a <italic>BRCA1</italic>ness tumor may be partially explained in this manner. Serine biosynthesis has been identified to be essential to tumorigenesis in estrogen receptor-negative breast cancer cell lines [<xref ref-type="bibr" rid="CR46">46</xref>]. We identified serine biosynthesis to be related specifically to the genes found in the <italic>BRCA1</italic>ness gene expression signature, suggesting that tumors having <italic>BRCA1</italic>-like features may have particular vulnerabilities to drugs that interfere with serine biosynthesis. It would be interesting to test whether high expression of genes involved in serine and glycine biosynthesis can confer sensitivity to drugs which interfere with this biosynthesis in breast cancer cell lines. In addition, we found that the signature is capable of predicting response to the PARP inhibitor veliparib in combination with carboplatin compared with a control treatment regimen.</p></sec><sec id="Sec11"><title>Conclusion</title><p id="Par49">The sample size in the I-SPY 2 TRIAL is small, but our prespecified analysis suggests that the <italic>BRCA1</italic>ness signature shows promise for predicting response to V-C combination therapy relative to control. We focused on the experimental arm of the study that contains DNA-damaging agents because the <italic>BRCA1</italic>ness test is meant to identify patients that may derive substantial benefit from these agents. We observed a proportion of patients who were hormone receptor-positive that benefited from the V-C treatment. It is unlikely in a regular clinical setting that hormone receptor-positive patients would be tested for <italic>BRCA1</italic>ness, but our data indicate that these patients could derive benefit from specific tailored treatments like PARP inhibitors and/or platinum agents. Concurrently reported results studying carboplatin in TN breast cancer have indicated it may be difficult to translate the pCR rate to longer benefit such as recurrence-free survival (RFS) [<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. It should be noted that, for this trial, we used a surrogate endpoint (pCR) for RFS and longer follow-up is required to investigate the <italic>BRCA1</italic>ness classifier in relation to long-term benefit. In the event that downsizing of the tumor is required to facilitate conversion from mastectomy to breast-conserving therapy, this classifier may already have value. If verified in a larger trial, this signature may contribute to the selection criteria of PARP inhibitor trials in the future.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec12"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13058_2017_861_MOESM1_ESM.xlsx"><label>Additional file 1:</label><caption><p>
<italic>BRCA1</italic>ness signature genes. (XLSX 40 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13058_2017_861_MOESM2_ESM.xlsx"><label>Additional file 2:</label><caption><p>I-SPY 2 Trial participating sites and institutional review boards (IRB). (XLSX 48 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ANOVA</term><def><p id="Par6">Analysis of variance</p></def></def-item><def-item><term>AUC</term><def><p id="Par7">Area under the curve</p></def></def-item><def-item><term>DLDA</term><def><p id="Par8">Diagonal linear discriminant analysis</p></def></def-item><def-item><term>EGFR</term><def><p id="Par9">Epidermal growth factor</p></def></def-item><def-item><term>ER&#x003b1;</term><def><p id="Par10">Estrogen receptor alpha</p></def></def-item><def-item><term>EU FP7</term><def><p id="Par11">European Union 7th Framework Programme</p></def></def-item><def-item><term>FF</term><def><p id="Par12">Fresh frozen</p></def></def-item><def-item><term>HER2</term><def><p id="Par13">Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>HR</term><def><p id="Par14">Hormone receptor status</p></def></def-item><def-item><term>HRD</term><def><p id="Par15">Homologous repair deficiency</p></def></def-item><def-item><term>I-SPY 2 TRIAL</term><def><p id="Par16">Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer</p></def></def-item><def-item><term>LOOCV</term><def><p id="Par17">Leave-one-out cross validation</p></def></def-item><def-item><term>MLPA</term><def><p id="Par18">Multiplex ligation-dependent probe amplification</p></def></def-item><def-item><term>NKI</term><def><p id="Par19">Netherlands Cancer Institute</p></def></def-item><def-item><term>OR</term><def><p id="Par20">Odds ratio</p></def></def-item><def-item><term>PARP</term><def><p id="Par21">Poly (ADP-ribose) polymerase</p></def></def-item><def-item><term>pCR</term><def><p id="Par22">Pathological complete response</p></def></def-item><def-item><term>PR</term><def><p id="Par23">Progesterone receptor</p></def></def-item><def-item><term>RATHER</term><def><p id="Par24">Rational Therapy for Breast Cancer</p></def></def-item><def-item><term>RIN</term><def><p id="Par25">RNA integrity number</p></def></def-item><def-item><term>ROC</term><def><p id="Par26">Receiver-operating characteristic</p></def></def-item><def-item><term>TN</term><def><p id="Par27">Triple-negative</p></def></def-item><def-item><term>V-C</term><def><p id="Par28">Veliparib&#x02013;carboplatin</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1186/s13058-017-0861-2) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to acknowledge all members of the RATHER Consortium: the collaborative European Union-funded effort FP7 RATHER project (<italic>Ra</italic>tional <italic>Ther</italic>apy for Breast Cancer) (protect number: 258967) (<ext-link ext-link-type="uri" xlink:href="http://www.ratherproject.com/">www.ratherproject.com</ext-link>). They also thank all I-SPY 2 TRIAL investigators and participants. In addition, the authors would like to acknowledge the effort and support of the Netherlands Cancer Institute (NKI) Core Facility Molecular Pathology and Biobanking (CFMPB) for supplying NKI Biobank material and support. The authors are grateful to Dr Esther Lips for supplying important data for preliminary analyses.</p><sec id="FPar1"><title>Funding</title><p id="Par50">This study was supported by the RATHER Consortium: the collaborative European Union-funded effort FP7 RATHER project (<italic>Ra</italic>tional <italic>Ther</italic>apy for Breast Cancer) (protect number: 258967) (<ext-link ext-link-type="uri" xlink:href="http://www.ratherproject.com/">www.ratherproject.com</ext-link>) and I-SPY 2 TRIAL investigators (ispy2.org).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par51">The datasets generated and/or analyzed during the current study are not publicly available due to ongoing analyses but are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>TMS, DMW, CY, JP, SL and Lv'tV all conceived of and designed the study. TMS, JP, DW, IMS, AMG and SL developed the BRCA1ness signature. PCS, S-FC, IJM, MM, BP and TB performed experiments and analyses on the validation set. DMW, CY, and Lv'tV analyzed I-SPY 2 TRIAL data.. LW, CC, RB, AMG, IMS, SL and Lv&#x02018;tV provided support and supervision. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par52">All patients for the I-SPY 2 clinical trial provided written informed consent. All participating sites received institutional review board approval (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2).</p></sec><sec id="FPar4"><title>Competing interests</title><p id="Par53">SL, TMS, IMS and JP are all named coinventors on a patent application for a <italic>BRCA</italic>ness gene expression classifier. PCS has a close relative employed by Astra-Zeneca. The remaining authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par54">All authors consent to publication.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par55">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>SP</given-names></name><name><surname>Chin</surname><given-names>S-F</given-names></name><name><surname>Turashvili</surname><given-names>G</given-names></name><name><surname>Rueda</surname><given-names>OM</given-names></name><name><surname>Dunning</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups</article-title><source>Nature</source><year>2012</year><volume>486</volume><issue>7403</issue><fpage>346</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">22522925</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linn</surname><given-names>SC</given-names></name><name><surname>van &#x02018;t Veer</surname><given-names>LJ</given-names></name></person-group><article-title>Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept</article-title><source>Eur J Cancer Oxf Engl 1990</source><year>2009</year><volume>45</volume><issue>Suppl 1</issue><fpage>11</fpage><lpage>26</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Adamo</surname><given-names>B</given-names></name><name><surname>Cheang</surname><given-names>MCU</given-names></name><name><surname>Anders</surname><given-names>CK</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Molecular characterization of basal-like and non-basal-like triple-negative breast cancer</article-title><source>Oncologist</source><year>2013</year><volume>18</volume><issue>2</issue><fpage>123</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2012-0397</pub-id><pub-id pub-id-type="pmid">23404817</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>TO</given-names></name><name><surname>Hsu</surname><given-names>FD</given-names></name><name><surname>Jensen</surname><given-names>K</given-names></name><name><surname>Cheang</surname><given-names>M</given-names></name><name><surname>Karaca</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma</article-title><source>Clin Cancer Res Off J Am Assoc Cancer Res</source><year>2004</year><volume>10</volume><issue>16</issue><fpage>5367</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0220</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blows</surname><given-names>FM</given-names></name><name><surname>Driver</surname><given-names>KE</given-names></name><name><surname>Schmidt</surname><given-names>MK</given-names></name><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>van Leeuwen</surname><given-names>FE</given-names></name><name><surname>Wesseling</surname><given-names>J</given-names></name><etal/></person-group><article-title>Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><issue>5</issue><fpage>e1000279</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000279</pub-id><pub-id pub-id-type="pmid">20520800</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>LC</given-names></name><name><surname>Martyniak</surname><given-names>A</given-names></name><name><surname>Kandel</surname><given-names>MJ</given-names></name><name><surname>Stadler</surname><given-names>ZK</given-names></name><name><surname>Masciari</surname><given-names>S</given-names></name><name><surname>Miron</surname><given-names>A</given-names></name><etal/></person-group><article-title>Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers</article-title><source>Am J Surg Pathol</source><year>2009</year><volume>33</volume><issue>7</issue><fpage>1093</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31819c1c93</pub-id><pub-id pub-id-type="pmid">19390427</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Stefansson</surname><given-names>IM</given-names></name><name><surname>Chappuis</surname><given-names>PO</given-names></name><name><surname>B&#x000e9;gin</surname><given-names>LR</given-names></name><name><surname>Goffin</surname><given-names>JR</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><etal/></person-group><article-title>Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer</article-title><source>J Natl Cancer Inst</source><year>2003</year><volume>95</volume><issue>19</issue><fpage>1482</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/jnci/djg050</pub-id><pub-id pub-id-type="pmid">14519755</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>A-R</given-names></name><name><surname>Kaldate</surname><given-names>RR</given-names></name><name><surname>Sailer</surname><given-names>LM</given-names></name><name><surname>Painter</surname><given-names>L</given-names></name><name><surname>Grier</surname><given-names>CE</given-names></name><name><surname>Endsley</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer</article-title><source>Cancer</source><year>2012</year><volume>118</volume><issue>11</issue><fpage>2787</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1002/cncr.26576</pub-id><pub-id pub-id-type="pmid">22614657</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwman</surname><given-names>P</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name></person-group><article-title>The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>9</issue><fpage>587</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nrc3342</pub-id><pub-id pub-id-type="pmid">22918414</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynahan</surname><given-names>ME</given-names></name><name><surname>Chiu</surname><given-names>JW</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><article-title>Brca1 controls homology-directed DNA repair</article-title><source>Mol Cell</source><year>1999</year><volume>4</volume><issue>4</issue><fpage>511</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80202-6</pub-id><pub-id pub-id-type="pmid">10549283</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedenfalk</surname><given-names>I</given-names></name><name><surname>Duggan</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Radmacher</surname><given-names>M</given-names></name><name><surname>Bittner</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gene-expression profiles in hereditary breast cancer</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><issue>8</issue><fpage>539</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1056/NEJM200102223440801</pub-id><pub-id pub-id-type="pmid">11207349</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000f6;nsson</surname><given-names>G</given-names></name><name><surname>Naylor</surname><given-names>TL</given-names></name><name><surname>Vallon-Christersson</surname><given-names>J</given-names></name><name><surname>Staaf</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><issue>17</issue><fpage>7612</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0570</pub-id><pub-id pub-id-type="pmid">16140926</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van&#x02019;t Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AAM</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><issue>6871</issue><fpage>530</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/415530a</pub-id><pub-id pub-id-type="pmid">11823860</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>MJ</given-names></name><name><surname>Kruse</surname><given-names>TA</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>L&#x000e6;nkholm</surname><given-names>A-V</given-names></name><name><surname>Bak</surname><given-names>M</given-names></name><name><surname>Lykkesfeldt</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e64268</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0064268</pub-id><pub-id pub-id-type="pmid">23704984</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>B</given-names></name><name><surname>Chin</surname><given-names>S-F</given-names></name><name><surname>Rueda</surname><given-names>OM</given-names></name><name><surname>Vollan</surname><given-names>H-KM</given-names></name><name><surname>Provenzano</surname><given-names>E</given-names></name><name><surname>Bardwell</surname><given-names>HA</given-names></name><etal/></person-group><article-title>The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes</article-title><source>Nat Commun.</source><year>2016</year><volume>7</volume><fpage>11479</fpage><pub-id pub-id-type="doi">10.1038/ncomms11479</pub-id><pub-id pub-id-type="pmid">27161491</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>EH</given-names></name><name><surname>Laddach</surname><given-names>N</given-names></name><name><surname>Savola</surname><given-names>SP</given-names></name><name><surname>Vollebergh</surname><given-names>MA</given-names></name><name><surname>Oonk</surname><given-names>AMM</given-names></name><name><surname>Imholz</surname><given-names>ALT</given-names></name><etal/></person-group><article-title>Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness</article-title><source>Breast Cancer Res</source><year>2011</year><volume>13</volume><issue>5</issue><fpage>R107</fpage><pub-id pub-id-type="doi">10.1186/bcr3049</pub-id><pub-id pub-id-type="pmid">22032731</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>EH</given-names></name><name><surname>Mulder</surname><given-names>L</given-names></name><name><surname>Hannemann</surname><given-names>J</given-names></name><name><surname>Laddach</surname><given-names>N</given-names></name><name><surname>Vrancken Peeters</surname><given-names>MTFD</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><issue>4</issue><fpage>870</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq468</pub-id><pub-id pub-id-type="pmid">20937646</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollebergh</surname><given-names>MA</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Linn</surname><given-names>SC</given-names></name></person-group><article-title>Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers</article-title><source>Cell Mol Life Sci</source><year>2012</year><volume>69</volume><issue>2</issue><fpage>223</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00018-011-0809-0</pub-id><pub-id pub-id-type="pmid">21922196</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schouten</surname><given-names>PC</given-names></name><name><surname>van Dyk</surname><given-names>E</given-names></name><name><surname>Braaf</surname><given-names>LM</given-names></name><name><surname>Mulder</surname><given-names>L</given-names></name><name><surname>Lips</surname><given-names>EH</given-names></name><name><surname>de Ronde</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Platform comparisons for identification of breast cancers with a BRCA-like copy number profile</article-title><source>Breast Cancer Res Treat</source><year>2013</year><volume>139</volume><issue>2</issue><fpage>317</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1007/s10549-013-2558-2</pub-id><pub-id pub-id-type="pmid">23670131</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessels</surname><given-names>LFA</given-names></name><name><surname>van Welsem</surname><given-names>T</given-names></name><name><surname>Hart</surname><given-names>AAM</given-names></name><name><surname>van&#x02019;t Veer</surname><given-names>LJ</given-names></name><name><surname>Reinders</surname><given-names>MJT</given-names></name><name><surname>Nederlof</surname><given-names>PM</given-names></name></person-group><article-title>Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>23</issue><fpage>7110</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12460933</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>CJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>BRCAness revisited</article-title><source>Nat Rev Cancer</source><year>2016</year><volume>16</volume><issue>2</issue><fpage>110</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/nrc.2015.21</pub-id><pub-id pub-id-type="pmid">26775620</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>Hallmarks of &#x0201c;BRCAness&#x0201d; in sporadic cancers</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><issue>10</issue><fpage>814</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nrc1457</pub-id><pub-id pub-id-type="pmid">15510162</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schouten</surname><given-names>PC</given-names></name><name><surname>Marm&#x000e9;</surname><given-names>F</given-names></name><name><surname>Aulmann</surname><given-names>S</given-names></name><name><surname>Sinn</surname><given-names>H-P</given-names></name><name><surname>van Essen</surname><given-names>HF</given-names></name><name><surname>Ylstra</surname><given-names>B</given-names></name><etal/></person-group><article-title>Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><issue>4</issue><fpage>763</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1894</pub-id><pub-id pub-id-type="pmid">25480832</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollebergh</surname><given-names>MA</given-names></name><name><surname>Lips</surname><given-names>EH</given-names></name><name><surname>Nederlof</surname><given-names>PM</given-names></name><name><surname>Wessels</surname><given-names>LFA</given-names></name><name><surname>Schmidt</surname><given-names>MK</given-names></name><name><surname>van Beers</surname><given-names>EH</given-names></name><etal/></person-group><article-title>An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><issue>7</issue><fpage>1561</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq624</pub-id><pub-id pub-id-type="pmid">21135055</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konstantinopoulos</surname><given-names>PA</given-names></name><name><surname>Spentzos</surname><given-names>D</given-names></name><name><surname>Karlan</surname><given-names>BY</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Fountzilas</surname><given-names>E</given-names></name><name><surname>Francoeur</surname><given-names>N</given-names></name><etal/></person-group><article-title>Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>22</issue><fpage>3555</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.27.5719</pub-id><pub-id pub-id-type="pmid">20547991</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Chun-Jen Lin</surname><given-names>C</given-names></name><name><surname>Mo</surname><given-names>W</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>Y-Y</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Genome-wide transcriptome profiling of homologous recombination DNA repair</article-title><source>Nat Commun.</source><year>2014</year><volume>5</volume><fpage>3361</fpage><pub-id pub-id-type="pmid">24553445</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J, et al. [S3-01] The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 2015;75(9 Supplement):S3-01-S3-01.</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schouten</surname><given-names>PC</given-names></name><name><surname>Linn</surname><given-names>SC</given-names></name></person-group><article-title>Challenges in the use of DNA repair deficiency as a biomarker in breast cancer</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><issue>17</issue><fpage>1867</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.60.5501</pub-id><pub-id pub-id-type="pmid">25918281</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>BD</given-names></name><name><surname>Bauer</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sanders</surname><given-names>ME</given-names></name><name><surname>Chakravarthy</surname><given-names>AB</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title><source>J Clin Invest</source><year>2011</year><volume>121</volume><issue>7</issue><fpage>2750</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1172/JCI45014</pub-id><pub-id pub-id-type="pmid">21633166</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Baggerly</surname><given-names>KA</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><etal/></person-group><article-title>Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><issue>19</issue><fpage>5533</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0799</pub-id><pub-id pub-id-type="pmid">23948975</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>K-D</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Zhan</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>AA</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Wong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer</article-title><source>Clin Cancer Res</source><year>2013</year><volume>19</volume><issue>10</issue><fpage>2723</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2986</pub-id><pub-id pub-id-type="pmid">23549873</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>H</given-names></name><name><surname>McCabe</surname><given-names>N</given-names></name><name><surname>Lord</surname><given-names>CJ</given-names></name><name><surname>Tutt</surname><given-names>ANJ</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Richardson</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title><source>Nature</source><year>2005</year><volume>434</volume><issue>7035</issue><fpage>917</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/nature03445</pub-id><pub-id pub-id-type="pmid">15829967</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, et al. BRCA1-like signature in triple negative breast cancer: molecular and clinical characterization reveals subgroups with therapeutic potential. Mol Oncol. 2015;8(7):1528&#x02013;38.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Liu</surname><given-names>MC</given-names></name><name><surname>Yee</surname><given-names>D</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>van&#x02019;t Veer</surname><given-names>LJ</given-names></name><name><surname>Symmans</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Adaptive randomization of neratinib in early breast cancer</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>1</issue><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1513750</pub-id><pub-id pub-id-type="pmid">27406346</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>DeMichele</surname><given-names>A</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>van &#x02018;t Veer</surname><given-names>LJ</given-names></name><name><surname>Buxton</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Adaptive randomization of veliparib-carboplatin treatment in breast cancer</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>1</issue><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1513749</pub-id><pub-id pub-id-type="pmid">27406347</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Wolf DM, Yau C, Sanil A, Glas A, Petricoin C, Wulfkuhle J, et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer (2017). <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/s41523-017-0025-7">http://dx.doi.org/10.1038/s41523-017-0025-7</ext-link></mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaut</surname><given-names>M</given-names></name><name><surname>Chin</surname><given-names>S-F</given-names></name><name><surname>Majewski</surname><given-names>I</given-names></name><name><surname>Severson</surname><given-names>TM</given-names></name><name><surname>Bismeijer</surname><given-names>T</given-names></name><name><surname>de Koning</surname><given-names>L</given-names></name><etal/></person-group><article-title>Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer</article-title><source>Sci Rep.</source><year>2016</year><volume>6</volume><fpage>18517</fpage><pub-id pub-id-type="doi">10.1038/srep18517</pub-id><pub-id pub-id-type="pmid">26729235</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Rabinovic</surname><given-names>A</given-names></name></person-group><article-title>Adjusting batch effects in microarray expression data using empirical Bayes methods</article-title><source>Biostat Oxf Engl</source><year>2007</year><volume>8</volume><issue>1</issue><fpage>118</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxj037</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glas</surname><given-names>AM</given-names></name><name><surname>Floore</surname><given-names>A</given-names></name><name><surname>Delahaye</surname><given-names>LJMJ</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Pover</surname><given-names>RCF</given-names></name><name><surname>Bakx</surname><given-names>N</given-names></name><etal/></person-group><article-title>Converting a breast cancer microarray signature into a high-throughput diagnostic test</article-title><source>BMC Genomics.</source><year>2006</year><volume>7</volume><fpage>278</fpage><pub-id pub-id-type="doi">10.1186/1471-2164-7-278</pub-id><pub-id pub-id-type="pmid">17074082</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Criscitiello</surname><given-names>C</given-names></name><name><surname>Azim</surname><given-names>HA</given-names><suffix>Jr</suffix></name><name><surname>Schouten</surname><given-names>PC</given-names></name><name><surname>Linn</surname><given-names>SC</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name></person-group><article-title>Understanding the biology of triple-negative breast cancer</article-title><source>Ann Oncol</source><year>2012</year><volume>23</volume><issue>Suppl 6</issue><fpage>vi13</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds188</pub-id><pub-id pub-id-type="pmid">23012296</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudis</surname><given-names>CA</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name></person-group><article-title>Triple-negative breast cancer: an unmet medical need</article-title><source>Oncologist.</source><year>2011</year><volume>16</volume><issue>Suppl 1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2011-S1-01</pub-id><pub-id pub-id-type="pmid">21278435</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fong</surname><given-names>PC</given-names></name><name><surname>Boss</surname><given-names>DS</given-names></name><name><surname>Yap</surname><given-names>TA</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Mergui-Roelvink</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>2</issue><fpage>123</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0900212</pub-id><pub-id pub-id-type="pmid">19553641</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J-M</given-names></name><name><surname>Ledermann</surname><given-names>JA</given-names></name><name><surname>Kohn</surname><given-names>EC</given-names></name></person-group><article-title>PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>1</issue><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt384</pub-id><pub-id pub-id-type="pmid">24225019</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Robson</surname><given-names>M</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Domchek</surname><given-names>SM</given-names></name><name><surname>Audeh</surname><given-names>MW</given-names></name><name><surname>Weitzel</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9737</issue><fpage>235</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60892-6</pub-id><pub-id pub-id-type="pmid">20609467</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>S-O</given-names></name><name><surname>Li</surname><given-names>C-W</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>H-H</given-names></name><name><surname>Chang</surname><given-names>S-S</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><etal/></person-group><article-title>EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape</article-title><source>Cancer Res</source><year>2016</year><volume>76</volume><issue>5</issue><fpage>1284</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2478</pub-id><pub-id pub-id-type="pmid">26759242</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Possemato</surname><given-names>R</given-names></name><name><surname>Marks</surname><given-names>KM</given-names></name><name><surname>Shaul</surname><given-names>YD</given-names></name><name><surname>Pacold</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name><etal/></person-group><article-title>Functional genomics reveal that the serine synthesis pathway is essential in breast cancer</article-title><source>Nature</source><year>2011</year><volume>476</volume><issue>7360</issue><fpage>346</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/nature10350</pub-id><pub-id pub-id-type="pmid">21760589</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Minckwitz</surname><given-names>G</given-names></name><name><surname>Schneeweiss</surname><given-names>A</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Salat</surname><given-names>C</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Rezai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>7</issue><fpage>747</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70160-3</pub-id><pub-id pub-id-type="pmid">24794243</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">von Minckwitz G, Loibl S, Schneeweiss A, Salat C, Rezai M, Zahm DM, et al. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). Cancer Res. 2016;76(4 Supplement):S2-04-S2-04.</mixed-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikov</surname><given-names>WM</given-names></name><name><surname>Berry</surname><given-names>DA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Cirrincione</surname><given-names>CT</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.57.0572</pub-id><pub-id pub-id-type="pmid">25092775</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/&#x02013; carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Cancer Res. 2016;76(4 Supplement):S2-05-S2-05.</mixed-citation></ref></ref-list></back></article>